StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research report released on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.
Organovo Price Performance
Shares of ONVO stock opened at $1.00 on Friday. The stock’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.12. Organovo has a fifty-two week low of $0.89 and a fifty-two week high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last announced its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.08 million. As a group, equities analysts predict that Organovo will post -1.74 earnings per share for the current fiscal year.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
See Also
- Five stocks we like better than Organovo
- Comparing and Trading High PE Ratio Stocks
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 4/22 – 4/26
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
